▶ 調査レポート

世界の進行性甲状腺がん治療用薬市場予測(~2028年):カボザンチニブ、ソラフェニブ、バンデタニブ、レンバチニブ

• 英文タイトル:Global Medicine for the Treatment of Advanced Thyroid Cancer Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

GlobalInfoResearchが調査・発行した産業分析レポートです。世界の進行性甲状腺がん治療用薬市場予測(~2028年):カボザンチニブ、ソラフェニブ、バンデタニブ、レンバチニブ / Global Medicine for the Treatment of Advanced Thyroid Cancer Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028 / GIR-22E8889資料のイメージです。• レポートコード:GIR-22E8889
• 出版社/出版日:GlobalInfoResearch / 2022年5月
• レポート形態:英文、PDF、96ページ
• 納品方法:Eメール(2~3営業日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥522,000 (USD3,480)▷ お問い合わせ
  Multi User¥783,000 (USD5,220)▷ お問い合わせ
  Corporate User¥1,044,000 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
進行性甲状腺がん治療用薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の進行性甲状腺がん治療用薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx%の成長率で成長すると予想されます。

進行性甲状腺がん治療用薬市場は種類と用途によって区分されます。2017年~2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・カボザンチニブ、ソラフェニブ、バンデタニブ、レンバチニブ

用途別セグメントは次のように区分されます。
・併用療法、単独薬

世界の進行性甲状腺がん治療用薬市場の主要な市場プレーヤーは以下のとおりです。
・Bayer、AstraZeneca、Sanofi、Exelixis Inc.、Ipsen Pharma、Eisai Inc

地域別セグメントは次の地域・国をカバーします。
・北米(米国、カナダ、メキシコ)
・ヨーロッパ(ドイツ、フランス、イギリス、ロシア、イタリア)
・アジア太平洋(日本、中国、韓国、インド、東南アジア、オーストラリア)
・南アメリカ(ブラジル、アルゼンチン、コロンビア)
・中東およびアフリカ(サウジアラビア、UAE、エジプト、南アフリカ)

本調査レポートの内容は計15章あります。
・第1章では、進行性甲状腺がん治療用薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な進行性甲状腺がん治療用薬メーカーの企業概要、2019年~2022年までの進行性甲状腺がん治療用薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な進行性甲状腺がん治療用薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年~2028年までの地域別進行性甲状腺がん治療用薬の販売量、売上、成長性を示しています。
・第5、6章では、2017年~2028年までの進行性甲状腺がん治療用薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年~2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年~2028年までの主要地域での進行性甲状腺がん治療用薬市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および進行性甲状腺がん治療用薬の産業チェーンを掲載しています。
・第13、14、15章では、進行性甲状腺がん治療用薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
・メーカー情報(企業概要、製品概要、販売量、価格、売上):Bayer、AstraZeneca、Sanofi、Exelixis Inc.、Ipsen Pharma、Eisai Inc
・メーカー別市場シェア
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年:カボザンチニブ、ソラフェニブ、バンデタニブ、レンバチニブ
・用途別分析2017年-2028年:併用療法、単独薬
・進行性甲状腺がん治療用薬の北米市場規模2017年-2028年:アメリカ、カナダ、メキシコ
・進行性甲状腺がん治療用薬のヨーロッパ市場規模2017年-2028年:ドイツ、イギリス、フランス、ロシア、イタリア
・進行性甲状腺がん治療用薬のアジア市場規模2017年-2028年:中国、日本、韓国、インド、東南アジア、オーストラリア
・進行性甲状腺がん治療用薬の南米市場規模2017年-2028年:ブラジル、アルゼンチン
・進行性甲状腺がん治療用薬の中東・アフリカ市場規模2017年-2028年:サウジアラビア、トルコ、エジプト、南アフリカ
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Medicine for the Treatment of Advanced Thyroid Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Medicine for the Treatment of Advanced Thyroid Cancer market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Combination therapy accounting for % of the Medicine for the Treatment of Advanced Thyroid Cancer global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Cabozantinib segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Medicine for the Treatment of Advanced Thyroid Cancer include Bayer, AstraZeneca, Sanofi, Exelixis Inc., and Ipsen Pharma, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Medicine for the Treatment of Advanced Thyroid Cancer market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Cabozantinib
Sorafenib
Vandetanib
Lenvatinib
Market segment by Application can be divided into
Combination therapy
Solo Medication
The key market players for global Medicine for the Treatment of Advanced Thyroid Cancer market are listed below:
Bayer
AstraZeneca
Sanofi
Exelixis Inc.
Ipsen Pharma
Eisai Inc
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Medicine for the Treatment of Advanced Thyroid Cancer product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Medicine for the Treatment of Advanced Thyroid Cancer, with price, sales, revenue and global market share of Medicine for the Treatment of Advanced Thyroid Cancer from 2019 to 2022.
Chapter 3, the Medicine for the Treatment of Advanced Thyroid Cancer competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Medicine for the Treatment of Advanced Thyroid Cancer breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Medicine for the Treatment of Advanced Thyroid Cancer market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Medicine for the Treatment of Advanced Thyroid Cancer.
Chapter 13, 14, and 15, to describe Medicine for the Treatment of Advanced Thyroid Cancer sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

1 Market Overview
1.1 Medicine for the Treatment of Advanced Thyroid Cancer Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Medicine for the Treatment of Advanced Thyroid Cancer Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Cabozantinib
1.2.3 Sorafenib
1.2.4 Vandetanib
1.2.5 Lenvatinib
1.3 Market Analysis by Application
1.3.1 Overview: Global Medicine for the Treatment of Advanced Thyroid Cancer Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Combination therapy
1.3.3 Solo Medication
1.4 Global Medicine for the Treatment of Advanced Thyroid Cancer Market Size & Forecast
1.4.1 Global Medicine for the Treatment of Advanced Thyroid Cancer Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Medicine for the Treatment of Advanced Thyroid Cancer Sales in Volume (2017-2028)
1.4.3 Global Medicine for the Treatment of Advanced Thyroid Cancer Price (2017-2028)
1.5 Global Medicine for the Treatment of Advanced Thyroid Cancer Production Capacity Analysis
1.5.1 Global Medicine for the Treatment of Advanced Thyroid Cancer Total Production Capacity (2017-2028)
1.5.2 Global Medicine for the Treatment of Advanced Thyroid Cancer Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Medicine for the Treatment of Advanced Thyroid Cancer Market Drivers
1.6.2 Medicine for the Treatment of Advanced Thyroid Cancer Market Restraints
1.6.3 Medicine for the Treatment of Advanced Thyroid Cancer Trends Analysis
2 Manufacturers Profiles
2.1 Bayer
2.1.1 Bayer Details
2.1.2 Bayer Major Business
2.1.3 Bayer Medicine for the Treatment of Advanced Thyroid Cancer Product and Services
2.1.4 Bayer Medicine for the Treatment of Advanced Thyroid Cancer Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca Medicine for the Treatment of Advanced Thyroid Cancer Product and Services
2.2.4 AstraZeneca Medicine for the Treatment of Advanced Thyroid Cancer Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Sanofi
2.3.1 Sanofi Details
2.3.2 Sanofi Major Business
2.3.3 Sanofi Medicine for the Treatment of Advanced Thyroid Cancer Product and Services
2.3.4 Sanofi Medicine for the Treatment of Advanced Thyroid Cancer Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Exelixis Inc.
2.4.1 Exelixis Inc. Details
2.4.2 Exelixis Inc. Major Business
2.4.3 Exelixis Inc. Medicine for the Treatment of Advanced Thyroid Cancer Product and Services
2.4.4 Exelixis Inc. Medicine for the Treatment of Advanced Thyroid Cancer Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Ipsen Pharma
2.5.1 Ipsen Pharma Details
2.5.2 Ipsen Pharma Major Business
2.5.3 Ipsen Pharma Medicine for the Treatment of Advanced Thyroid Cancer Product and Services
2.5.4 Ipsen Pharma Medicine for the Treatment of Advanced Thyroid Cancer Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Eisai Inc
2.6.1 Eisai Inc Details
2.6.2 Eisai Inc Major Business
2.6.3 Eisai Inc Medicine for the Treatment of Advanced Thyroid Cancer Product and Services
2.6.4 Eisai Inc Medicine for the Treatment of Advanced Thyroid Cancer Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Medicine for the Treatment of Advanced Thyroid Cancer Breakdown Data by Manufacturer
3.1 Global Medicine for the Treatment of Advanced Thyroid Cancer Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Medicine for the Treatment of Advanced Thyroid Cancer Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Medicine for the Treatment of Advanced Thyroid Cancer
3.4 Market Concentration Rate
3.4.1 Top 3 Medicine for the Treatment of Advanced Thyroid Cancer Manufacturer Market Share in 2021
3.4.2 Top 6 Medicine for the Treatment of Advanced Thyroid Cancer Manufacturer Market Share in 2021
3.5 Global Medicine for the Treatment of Advanced Thyroid Cancer Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Medicine for the Treatment of Advanced Thyroid Cancer Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Medicine for the Treatment of Advanced Thyroid Cancer Market Size by Region
4.1.1 Global Medicine for the Treatment of Advanced Thyroid Cancer Sales in Volume by Region (2017-2028)
4.1.2 Global Medicine for the Treatment of Advanced Thyroid Cancer Revenue by Region (2017-2028)
4.2 North America Medicine for the Treatment of Advanced Thyroid Cancer Revenue (2017-2028)
4.3 Europe Medicine for the Treatment of Advanced Thyroid Cancer Revenue (2017-2028)
4.4 Asia-Pacific Medicine for the Treatment of Advanced Thyroid Cancer Revenue (2017-2028)
4.5 South America Medicine for the Treatment of Advanced Thyroid Cancer Revenue (2017-2028)
4.6 Middle East and Africa Medicine for the Treatment of Advanced Thyroid Cancer Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Medicine for the Treatment of Advanced Thyroid Cancer Sales in Volume by Type (2017-2028)
5.2 Global Medicine for the Treatment of Advanced Thyroid Cancer Revenue by Type (2017-2028)
5.3 Global Medicine for the Treatment of Advanced Thyroid Cancer Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Medicine for the Treatment of Advanced Thyroid Cancer Sales in Volume by Application (2017-2028)
6.2 Global Medicine for the Treatment of Advanced Thyroid Cancer Revenue by Application (2017-2028)
6.3 Global Medicine for the Treatment of Advanced Thyroid Cancer Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Medicine for the Treatment of Advanced Thyroid Cancer Sales by Type (2017-2028)
7.2 North America Medicine for the Treatment of Advanced Thyroid Cancer Sales by Application (2017-2028)
7.3 North America Medicine for the Treatment of Advanced Thyroid Cancer Market Size by Country
7.3.1 North America Medicine for the Treatment of Advanced Thyroid Cancer Sales in Volume by Country (2017-2028)
7.3.2 North America Medicine for the Treatment of Advanced Thyroid Cancer Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Medicine for the Treatment of Advanced Thyroid Cancer Sales by Type (2017-2028)
8.2 Europe Medicine for the Treatment of Advanced Thyroid Cancer Sales by Application (2017-2028)
8.3 Europe Medicine for the Treatment of Advanced Thyroid Cancer Market Size by Country
8.3.1 Europe Medicine for the Treatment of Advanced Thyroid Cancer Sales in Volume by Country (2017-2028)
8.3.2 Europe Medicine for the Treatment of Advanced Thyroid Cancer Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Medicine for the Treatment of Advanced Thyroid Cancer Sales by Type (2017-2028)
9.2 Asia-Pacific Medicine for the Treatment of Advanced Thyroid Cancer Sales by Application (2017-2028)
9.3 Asia-Pacific Medicine for the Treatment of Advanced Thyroid Cancer Market Size by Region
9.3.1 Asia-Pacific Medicine for the Treatment of Advanced Thyroid Cancer Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Medicine for the Treatment of Advanced Thyroid Cancer Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Medicine for the Treatment of Advanced Thyroid Cancer Sales by Type (2017-2028)
10.2 South America Medicine for the Treatment of Advanced Thyroid Cancer Sales by Application (2017-2028)
10.3 South America Medicine for the Treatment of Advanced Thyroid Cancer Market Size by Country
10.3.1 South America Medicine for the Treatment of Advanced Thyroid Cancer Sales in Volume by Country (2017-2028)
10.3.2 South America Medicine for the Treatment of Advanced Thyroid Cancer Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Medicine for the Treatment of Advanced Thyroid Cancer Sales by Type (2017-2028)
11.2 Middle East & Africa Medicine for the Treatment of Advanced Thyroid Cancer Sales by Application (2017-2028)
11.3 Middle East & Africa Medicine for the Treatment of Advanced Thyroid Cancer Market Size by Country
11.3.1 Middle East & Africa Medicine for the Treatment of Advanced Thyroid Cancer Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Medicine for the Treatment of Advanced Thyroid Cancer Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Medicine for the Treatment of Advanced Thyroid Cancer and Key Manufacturers
12.2 Manufacturing Costs Percentage of Medicine for the Treatment of Advanced Thyroid Cancer
12.3 Medicine for the Treatment of Advanced Thyroid Cancer Production Process
12.4 Medicine for the Treatment of Advanced Thyroid Cancer Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Medicine for the Treatment of Advanced Thyroid Cancer Typical Distributors
13.3 Medicine for the Treatment of Advanced Thyroid Cancer Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer